Biocon Limited — Q4 FY26
Biocon delivered a strong Q4 FY26, with adjusted revenue growth of 10% YoY and EBITDA up 29% YoY to ₹1,073 crore, driven by favorable mix and operating leverage in biosimilars.
bullish
high
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
77%Questions answered1Evaded / deflected11Questions auditedContradictedNumbers vs filing
Partial answer
High priority
Biosimilar revenue trajectory and stabilization after Q3 disruption.
Asked by Niha Manpurya, Bank of America
Answered Q3-Q4 growth but avoided giving forward guidance on FI27/FI28.
no specific guidance on FI27/FI28reframed to sequential growth
Read the exchange
Question
how should we think about FI27 FI28 given we have had some launches... we haven't really seen material improvement in biosimilar revenue... is it fair to assume that full stabilization of that disruption that we saw in the third quarter is not yet done.
Shriram (CEO)
If you look at the numbers between Q3 and Q4, you are seeing a sequential change where we moved from a quarter which was 279 to $80 million to about $30 plus million this quarter. So there's a sequential growth of 12% that you are seeing on a rupee basis in the revenues.
Answered
High priority
Deleveraging plan and free cash flow usage in FY27.
Asked by Niha Manpurya, Bank of America
Provided specific debt reduction numbers and confirmed priority of deleveraging.
Read the exchange
Question
how should we think about deleveraging in fiscal 27... is it fair to assume that all of the free capital generation that we have would be largely used for deleveraging any color there
Kedar (CFO)
every dollar that we generate out of free cash the first claim is going to be to reduce the debt... In March 25, including structured instruments, we had in fact more than $1.5 billion of net debt. That's down to 1.1 now.
Answered
High priority
Biosimilar sales split between developed and rest of world, and product launch outlook.
Asked by Damyanti Kerai
Provided approximate split and discussed product launch plans.
Read the exchange
Question
if you can give us split for fi26 sales between developed market and rest of the world and then if you can comment on two specific product where you will be coming soon in the market as per your settlement date.
Shriram (CEO)
our distribution is pretty diversified... roughly norm at 40 35 in with Europe and 25 emerging markets... roughly 7525 if you're asking advanced markets and emerging markets could be between 7822 in a particular quarter.
Partial answer
Medium priority
Capital allocation and R&D focus after capex investments.
Asked by Damyanti Kerai
Addressed capex but did not detail specific R&D products or pipeline.
no specific R&D pipeline detailsdeferred to consolidation
Read the exchange
Question
just wanted to have some more color on your focus in R&D what kind of products you can add onto your portfolio say 2 to 3 years down the line and apart from the Malaysia plant do you have any other capex remaining
Shriram (CEO)
capital allocation is largely behind us... operating leverage starting to kick in... we consolidate the business in the next four quarters and set it up for acceleration in the coming fiscal.
Declined
Low priority
Clarification on large other comprehensive income items.
Asked by Sanjay Kohli, Goldstone Capital
Refused to answer on the call, deferred to offline discussion.
took offlineno explanation given
Read the exchange
Question
under the head items that will be classified to reclassify to P&L later there's a large number of 760 for the quarter and then which will not be reclassified about 210 crores. So what exactly is this?
Kedar (CFO)
I'll take it offline. Let's get in touch after the call. We have full backup.
Answered
High priority
Impact of FDA draft guidelines reducing R&D costs for biosimilars.
Asked by Anishh Bman, Varia
Provided specific impact on cost and timeline, and explained competitive advantage.
Read the exchange
Question
we saw some draft guidelines coming from the FDA which talked about significantly reducing the R&D cost to get new biosimilars in the market. So I just wanted your opinion on how that impacts one bioon's existing products and second the pipeline.
Shriram (CEO)
it has reduced the development cost by 50%... accelerated products from a development standpoint by at least 3 to four years... gives companies like Bioon an advantage given our proven track record in CMC compatibility.
Answered
High priority
Constant currency sales by division and update on $200 million product benchmark.
Asked by Sedhart Nandhi, CWC
Provided constant currency growth and updated product revenue milestones.
Read the exchange
Question
could you give us an understanding of the constant currency sales in each of the divisions... the dollar20 million benchmark that you had shared last year if you could give us an update on both of those the market shares as well as the number of products that are above $200 million in bioimilars.
Kedar (CFO)
biosimilars we are saying it's 12% growth year on year in this quarter the dollar growth will be about 7%... insulin now has cost 300 million... Adali mumab is now beyond 250 million... beasumap has crossed 100 million now.
Partial answer
Medium priority
Biosimilar capacity utilization and need for further expansion.
Asked by Tushar Manuhan, Motilan
Gave directional answer but avoided specific utilization percentage.
no single utilization number givenvague on exact capacity
Read the exchange
Question
what could be the capacity utilization currently... from a capacity standpoint do we really need further capacity expansion or the current capacity would be good enough to drive growth for FI2728 in particular?
Kedar (CFO)
capacities do remain healthy... as of now we don't see any need for a large green field capex... Malaysia doubling... will get operational soon.
Answered
High priority
Generics business scale-up and margin improvement drivers.
Asked by Tushar Manuhan, Motilan
Provided gross margin range and identified growth driver (GLP1).
Read the exchange
Question
how to think about the scale up of this business and subsequently the margin improvement... what's the gross margin currently and how the operating leverage will play out
Kedar (CFO)
gross margins are in early 40s... the GLP1 revenues which were about less than 10% of the overall business last year in FI26 that will scale up... operating leverage kicks in the coming quarters.
Answered
Medium priority
Hedging policy on US dollar bonds and call option thoughts.
Asked by Mtia Sheffoden, Barclays
Explained natural hedge and provided current thinking on call option.
Read the exchange
Question
would you be able to provide some color on your hedging policy... your bonds become collable from October this year... how are you thinking on the bonds given that your US dollar bonds are at 6.67% coupon
Kedar (CFO)
on the bonds we don't have to hedge because we have a natural hedge... we are watching the situation. We have to evaluate whether it makes sense to pay the call premium.
Evasive
High priority
US biosimilar momentum and share of US business in FY27.
Asked by Surya Patra, Tuliv Capital
Avoided giving quantitative outlook on US business share or momentum.
no specific momentum or share numbersreframed to profitability
Read the exchange
Question
what is the kind of a momentum that we would see for the US business and what is the likely share of US business in FI27 versus FI26
Shriram (CEO)
market share is not necessarily the only proxy for success... we've been very careful as we picked up market shares... our focus is always profitable growth and not necessarily market shares.
Answered
Medium priority
Biosimilar sales breakdown by geography and largest product.
Asked by Vishal Mananda, systematics
Provided geographic split and product revenue ranges.
Read the exchange
Question
can you break up your biosimilar sales between US emerging US Europe and the rest of world?
Kedar (CFO)
North America is about 40 Europe and little of Japan 35 and emerging market 25... total insulin franchise globally is cross 300 million adali mumbai globally again is beyond 250 million.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| Biosimilar sequential growth 12% on rupee basis | 12% | 10% | Overstated vs filing |
| Biosimilar dollar growth about 7% YoY | 7% | 10% | Understated vs filing |
| Insulin franchise crossed $300 million | 300 | 4,517 | Understated vs filing |
| Adalimumab beyond $250 million | 250 | 4,517 | Understated vs filing |
| Bevacizumab crossed $100 million | 100 | 4,517 | Understated vs filing |
| Generics EBITDA margin roughly 10% in Q4 | 10% | 23% | Understated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.